Chengdu Yazhong Bio-pharmaceutical

Chengdu Yazhong Bio-pharmaceutical is a research and development-focused subsidiary of the Yangtze River Pharmaceutical Group, located in Chengdu, China. The company specializes in the discovery and development of innovative small molecule drugs, particularly in the field of central nervous system (CNS) disorders. Its lead candidate, YZJ-1139, is a dual orexin receptor antagonist (DORA) developed for the treatment of insomnia, which has shown promising results in clinical trials. The company leverages the extensive manufacturing and commercialization infrastructure of its parent group to bring new therapies to the Chinese market. Its strategic location in the Chengdu High-tech Zone allows it to tap into a rich pool of regional talent and academic resources.